Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10373066" target="_blank" >RIV/00216208:11110/18:10373066 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/18:10373066
Result on the web
<a href="https://doi.org/10.1016/j.msard.2017.11.018" target="_blank" >https://doi.org/10.1016/j.msard.2017.11.018</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.msard.2017.11.018" target="_blank" >10.1016/j.msard.2017.11.018</a>
Alternative languages
Result language
angličtina
Original language name
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod
Original language description
Background: Fingolimod is an efficient and safe drug for treating relapsing-remitting multiple sclerosis (RRMS). In vivo, fingolimod is phosphorylated and binds to "sphingosine-1-phosphate"(S1P) receptors that are expressed in a wide range of cells, including lymphocytes. Under the effect of fingolimod, lymphocytes are retained in lymphoid tissues through the regulation of S1P(1) receptors. The aim of the present study was to assess whether the degree of lymphopenia was correlated to the positive treatment response of RRMS patients with fingolimod. Methods: Data was sourced from the MSBase Registry. Patients were divided into two groups, according to the lymphocyte count on peripheral blood examination. Annualized Relapse Rate (ARR), time to first relapse and time to six-month confirmed disability progression were compared between groups. Results: Group one consisted of 202 patients who reached 750 lymphocytes/mm(3) during treatment while the comparison group two included 101 patients who never reached less than 1000 lymphocytes/mm(3) in peripheral blood during the observation period. There were no differences between groups in ARR, time to first relapse or time to six-month confirmed disability progression. Conclusion: The degree of lymphopenia in peripheral blood was not associated to the positive treatment response of fingolimod in RRMS patients.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30103 - Neurosciences (including psychophysiology)
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Multiple Sclerosis and Related Disorders
ISSN
2211-0348
e-ISSN
—
Volume of the periodical
19
Issue of the periodical within the volume
January
Country of publishing house
US - UNITED STATES
Number of pages
4
Pages from-to
105-108
UT code for WoS article
000425903700023
EID of the result in the Scopus database
2-s2.0-85034851540